# Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression

Source: https://onco.cc/trials/nct07655622/  
OnCo record `nct07655622` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of vebreltinib in lung cancer, run by Second Affiliated Hospital of Nanchang University, now recruiting.

## Summary

Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression is a phase 1/2, interventional study registered as NCT07655622 by Second Affiliated Hospital of Nanchang University, with a registry enrolment figure of 45 participants, started 2026-07-03 and due to reach its primary completion in 2027-12-03. Interventions recorded: Vebreltinib; Furmonertinib 80mg. Conditions listed: Non-Small-Cell Lung Cancer. Primary outcome: Phase Ib: Incidence of Dose-Limiting Toxicities as assessed by protocol-defined criteria and CTCAE v5.0; Phase Ib: Incidence of Grade ≥2 Treatment-Emergent Adverse Events as assessed by CTCAE v5.0; Phase Ib: Rate of dose reduction, interruption, or discontinuation due to treatment-related adverse ev. Lung eligibility wording from the registry: "Histologically or cytologically confirmed locally advanced (stage IIIB-IIIC), metastatic, or recurrent (stage IV) non-small cell lung cancer, not amenable to surgical resection and definitive concurrent chemoradiotherapy". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: DUAL-THRUST
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07655622
- Phase: 1/2
- Setting: A Single-arm, Phase I/II Trial Aimed to Evaluate the Efficacy and Safety of Vebreltinib Plus Furmonertinb as First-line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring EGFR Mutations and High PD-L1 Expression
- Sponsor: Second Affiliated Hospital of Nanchang University
- Enrolled: 45

## Sources

- ClinicalTrials.gov NCT07655622: https://clinicaltrials.gov/study/NCT07655622

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/)
- drugs: [Vebreltinib](https://onco.cc/drugs/vebreltinib/)
- companies: [Beijing Pearl Biotechnology Limited Liability Company](https://onco.cc/companies/beijing-pearl-biotechnology-limited-liability-company/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07655622.json